0001564590-22-004708.txt : 20220211 0001564590-22-004708.hdr.sgml : 20220211 20220211094806 ACCESSION NUMBER: 0001564590-22-004708 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220210 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220211 DATE AS OF CHANGE: 20220211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Metacrine, Inc. CENTRAL INDEX KEY: 0001634379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472297384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39512 FILM NUMBER: 22617221 BUSINESS ADDRESS: STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-369-7800 MAIL ADDRESS: STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 mtcr-8k_20220210.htm 8-K mtcr-8k_20220210.htm
false 0001634379 0001634379 2022-02-10 2022-02-10

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 10, 2022

 

Metacrine, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39512

47-2297384

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

3985 Sorrento Valley Blvd., Suite C

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 369-7800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

MTCR

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ 

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On February 11, 2022, Metacrine, Inc. (the “Company”) announced an estimate regarding its cash, cash equivalents and short-term investments as of December 31, 2021, and the Company’s belief that it has sufficient working capital to fund its current operating plan through the year ending December 31, 2023 (such information, the “Financial Condition Information”). The Financial Condition Information represents preliminary estimates based on currently available information and does not present all necessary information for a complete understanding of the Company’s financial condition as of December 31, 2021 or the Company’s results of operations for the year ended December 31, 2021. The estimated cash, cash equivalents and short-term investments figure is preliminary, unaudited and subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated cash, cash equivalents and short-term investments figure.

On February 11, 2022, the Company issued a press release containing the Financial Condition Information, and announcing the Restructuring Plan (as defined and disclosed below under Item 2.05).  A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference. The information set forth in this Item 2.02, including Exhibit 99.1 attached hereto, is to be deemed furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 2.05 Costs Associated with Exit or Disposal Activities.

On February 10, 2022, the Company implemented a restructuring plan (the “Restructuring Plan”) designed to reduce the Company’s operating expenses, preserve cash and align its resources to support the ongoing clinical development of MET642 in inflammatory bowel disease. As part of the Restructuring Plan, the Company has discontinued preclinical development of its hydroxysteroid dehydrogenase (“HSD”) program and implemented a staff reduction of approximately 50%, primarily consisting of the Company’s research organization. The Company estimates that it will incur aggregate costs related to the Restructuring Plan ranging from $1.1 million to $1.3 million, substantially all of which will consist of one-time charges arising from severance obligations, accelerated vesting of certain equity awards and other customary employee benefits payments in connection with the staff reduction, but will include third-party research and development expenses incidental to the discontinuation of the Company’s HSD program. Substantially all of the committed actions under the Restructuring Plan have been completed. The estimates of the costs the Company expects to incur, and the successful implementation of the restructuring activities pursuant to the Restructuring Plan, are subject to a number of assumptions, risks and uncertainties, and actual results may differ from the above-described estimates. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Restructuring Plan.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 10, 2022, Kristina Burow informed the Board of Directors (the “Board”) of her resignation as a member of the Board, the Audit Committee of the Board (the “Audit Committee”) and the Nominating and Corporate Governance Committee of the Board, effective immediately. Ms. Burow’s resignation was not related to any disagreement with the Company over any of its operations, policies or practices. Effective immediately upon Ms. Burow’s resignation, the Board decreased the authorized number of directors from nine (9) to eight (8), and the number of directors comprising Class II of the Board from three (3) to two (2).

On February 10, 2022, effective immediately upon Ms. Burow’s resignation, the Board appointed Jeffrey Jonker, a current director, to the Audit Committee to fill the vacancy resulting from Ms. Burow’s resignation. The Board previously determined that Mr. Jonker qualifies as independent under the director independence standards set forth in the rules and regulations of the Securities and Exchange Commission (the “SEC”) and the applicable listing standards of The Nasdaq Stock Market (“Nasdaq”), and in connection with Mr. Jonker’s appointment to the Audit Committee further determined that he satisfies the additional requirements of financial literacy and audit committee independence for audit committee service under applicable SEC rules and regulations and Nasdaq listing standards.

Forward-Looking Statements

This Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this Current Report on Form 8-K that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, estimates of the Company’s cash, cash equivalents and short-term investments balance as of December 31, 2021; the Company’s belief that it has sufficient working capital to fund its current operating plan through the year ending 2023; the expected benefits of the Restructuring Plan, including its potential to reduce the Company’s operating expenses, preserve cash and align its resources to support the ongoing clinical development of MET642 in inflammatory bowel disease; estimates for expenses that will be incurred pursuant to the Restructuring Plan; statements about the Company’s plans and timing for initiating future clinical trials and studies; and anticipated near- and long-term drivers of value. Words such as “may,” “will,” “expect,” “plan,” “aim,” “projected,” “likely,” “anticipate,” “estimate,”

1

 

“intend,” “potential,” “prepare,” “perceived,” “believes” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s expectations and assumptions that may never materialize or prove to be incorrect. Each of these forward-looking statements involves risks and uncertainties, many of which may be beyond the Company’s control. Actual results may differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks and uncertainties regarding regulatory approvals for MET642; potential delays in initiating, enrolling or completing any clinical trials; potential adverse side effects or other safety risks associated with the Company’s product candidates; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s ability to successfully implement its Restructuring Plan, including realizing the expected cost savings and other benefits from implementation of the Restructuring Plan discussed in this Current Report on Form 8-K.  Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 12, 2021, and in the Company’s other filings with the SEC. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

The following exhibit is furnished with this Current Report.

 

Exhibit

Number

 

Description

99.1

 

Press release dated February 11, 2022

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Metacrine, Inc.

 

 

 

 

Date: February 11, 2022

 

By:

/s/ Patricia Millican

 

 

 

Patricia Millican

 

 

 

Chief Financial Officer

 

3

 EX-99.1 2 mtcr-ex991_29.htm EX-99.1 mtcr-ex991_29.htm

Exhibit 99.1

 

METACRINE UPDATES IBD CLINICAL DEVELOPMENT STRATEGY AND IMPLEMENTS RESTRUCTURING PLAN

- U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitis

- Sufficient capital to complete Phase 2 IBD trial

 

SAN DIEGO – February 11, 2022 -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that it remains on track to begin a Phase 2 clinical trial in ulcerative colitis. Metacrine has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with its Phase 2 trial evaluating MET642 in subjects with inflammatory bowel disease (IBD) and expects to begin the study in the first half of 2022.    

To support ongoing clinical development of MET642 in IBD, the Company is implementing a restructuring plan to significantly reduce expenses associated with its operations in order to preserve cash. The restructuring includes a staff reduction of approximately 50% primarily consisting of the Company’s research organization. As a result, Metacrine has also discontinued preclinical development of its hydroxysteroid dehydrogenase (HSD) program. Cash, cash equivalents and short-term investments were an estimated $76.4 million as of December 31, 2021. Metacrine believes it has sufficient capital to fund its current operating plan through 2023.     

 

“We are now focusing all of our development effort on bringing expanded therapeutic options to people living with IBD,” said Preston Klassen, M.D., MHS, CEO, Metacrine. “We have generated preclinical data that supports moving our MET642 program into clinical testing in IBD during the next few months. The rationale for FXR-based therapies in IBD is anchored on the potential to address multiple aspects of IBD pathogenesis without the immunosuppression inherent to other advanced-line therapies. FXR is highly expressed by intestinal epithelial cells and plays a key role in healthy intestinal function by maintaining the epithelial barrier, reducing bacterial translocation into the intestinal wall and regulating the innate immune response. FXR therapy could bring an oral, once-daily, well-tolerated and non-immunosuppressive medicine to patients.”

 

Klassen continued, “We’re also taking restructuring steps to manage our resources and significantly extend our cash runway as we evaluate a range of ways to generate value from our discovery programs, product candidates and financial assets. I am grateful for the dedication of my fellow colleagues to our mission and thank them for their many contributions over the last several years.”

 

About Metacrine

Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat gastrointestinal and liver diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. To learn more, visit www.metacrine.com.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements about Metacrine’s plans and timing for initiating future clinical trials and studies; the expected benefits of its restructuring plans, including expected cost savings provided by the restructuring; anticipated near and long term drivers of value; estimates for its cash, cash equivalents and short-term investments balance as of December 31, 2021; and its belief that it has sufficient capital to fund its current operating plan through 2023. Words such as “may,” “will,” “expect,” “plan,” “aim,” “projected,” “likely,” “anticipate,” “estimate,” “intend,” “potential,” “prepare,” “perceived,” “believes” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Metacrine’s expectations and assumptions that may never materialize or prove to be incorrect. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks and uncertainties regarding regulatory approvals for MET642; potential delays in initiating, enrolling or completing any clinical trials; potential adverse side effects or other safety risks associated with Metacrine’s product candidates; competition from third parties that are developing products for similar uses; Metacrine’s ability to obtain, maintain and protect its intellectual property; and Metacrine’s ability to successfully implement its restructuring plans, including expected cost savings provided by the restructuring.  Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in Metacrine’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2021, and in Metacrine’s other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as required by law, Metacrine assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

Investor & Media Contact

Investor Relations

Metacrine, Inc.

Investors@metacrine.com

 EX-101.SCH 3 mtcr-20220210.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mtcr-20220210_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Central Index Key Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 5 mtcr-20220210_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Feb. 10, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Entity Registrant Name Metacrine, Inc.
Document Period End Date Feb. 10, 2022
Entity Central Index Key 0001634379
Entity File Number 001-39512
Entity Incorporation State Country Code DE
Entity Tax Identification Number 47-2297384
Entity Address, Address Line One 3985 Sorrento Valley Blvd.
Entity Address, Address Line Two Suite C
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 369-7800
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period true
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol MTCR
Security Exchange Name NASDAQ
XML 7 mtcr-8k_20220210_htm.xml IDEA: XBRL DOCUMENT 0001634379 2022-02-10 2022-02-10 false 0001634379 8-K 2022-02-10 Metacrine, Inc. DE 001-39512 47-2297384 3985 Sorrento Valley Blvd. Suite C San Diego CA 92121 858 369-7800 false false false false Common Stock, par value $0.0001 per share MTCR NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports mtcr-8k_20220210.htm mtcr-20220210.xsd mtcr-20220210_lab.xml mtcr-20220210_pre.xml mtcr-ex991_29.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mtcr-8k_20220210.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "mtcr-8k_20220210.htm" ] }, "labelLink": { "local": [ "mtcr-20220210_lab.xml" ] }, "presentationLink": { "local": [ "mtcr-20220210_pre.xml" ] }, "schema": { "local": [ "mtcr-20220210.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mtcr", "nsuri": "http://www.metacrine.com/20220210", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mtcr-8k_20220210.htm", "contextRef": "C_0001634379_20220210_20220210", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mtcr-8k_20220210.htm", "contextRef": "C_0001634379_20220210_20220210", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.metacrine.com/20220210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001564590-22-004708-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-004708-xbrl.zip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end